Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS guide helps tech companies with approval process

This article was originally published in The Gray Sheet

Executive Summary

Medicare agency says Aug. 25 its new "Innovator's Guide to Navigating CMS" is available online at 1http://www.cms.hhs.gov/CouncilonTechInnov/. Developed by the CMS Council for Technology and Innovation, it marks the first time CMS has presented detailed information on Medicare coverage, coding and payment in a single document

You may also be interested in...



CMS In Brief

More coverage with evidence development?: Coverage with evidence development, in which Medicare covers services or devices only through clinical trials or data registries, has been "indeed successful," said Barry Straube, director and chief clinical officer of CMS' Office of Clinical Standards and Quality, at the AdvaMed 2009 conference in Washington, D.C., Oct. 13. The coverage approach has been most successful in PET scanning, where "we've found we're getting evidence that PET scanning is reasonable and necessary for a number of cancers, and we've added full coverage in those areas," Straube said. "I think this is something we haven't fully utilized and will be utilizing more.

Can Organovo Leverage Its Solid Phase II Data In MASH?

Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.

Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune

The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026505

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel